How to Get Evenity (Romosozumab) in Washington

Who Qualifies for Romosozumab in Washington

Romosozumab is not a first-line osteoporosis drug. The FDA approved it in April 2019 specifically for postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of other osteoporosis therapies [1]. Washington Medicaid and most commercial plans in the state follow these same criteria.

The ARCH trial (N=4,093) demonstrated that romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months, and reduced hip fractures by 38% [2]. These results drove the drug's positioning as a treatment for patients whose fracture risk is too high to wait for bisphosphonates to reach full effect.

In practice, Washington prescribers typically consider you a candidate if your DXA T-score is −2.5 or below at the lumbar spine or femoral neck, you have had a prior fragility fracture, or your FRAX 10-year major osteoporotic fracture probability exceeds 20%. Patients who have failed or cannot tolerate bisphosphonates often qualify more readily for prior authorization.

The boxed warning on Evenity's label notes increased cardiovascular risk. Patients who have had a myocardial infarction or stroke within the preceding year should not receive romosozumab [1]. Washington prescribers must document cardiovascular risk assessment before initiating therapy.

Telehealth Prescribing of Romosozumab in Washington

Washington state permits telehealth prescribing of romosozumab. The state's telemedicine parity law (RCW 48.43.735) requires insurers to cover services delivered via telemedicine to the same extent as in-person visits, which means your initial consultation, lab review, and prescription can happen remotely [3].

A telehealth visit for romosozumab typically proceeds in three stages. First, a board-certified endocrinologist, rheumatologist, or qualified prescriber reviews your DXA results and fracture history via video. Second, they order or review the required baseline labs (discussed below). Third, they submit the prior authorization request to your insurer while sending the prescription to a specialty pharmacy.

The injection itself requires two subcutaneous shots (each prefilled syringe delivers 105 mg for a total dose of 210 mg). Most patients self-administer at home after a teaching session, though some Washington clinics offer in-office administration. Telehealth providers can arrange a one-time in-person or video-guided injection training for your first dose.

Washington's Department of Health does not require an in-person visit before a prescriber can issue a romosozumab prescription, provided the standard of care is met through the telehealth encounter. This makes Washington one of the more accessible states for patients in rural areas east of the Cascades who may be hours from the nearest endocrinology clinic.

Required Labs Before Starting Evenity in Washington

Before any Washington prescriber initiates romosozumab, a specific set of labs must be on file. These are not optional. Insurers will deny prior authorization if the supporting documentation is incomplete.

The baseline panel includes serum calcium (to rule out hypocalcemia, which romosozumab can worsen), 25-hydroxyvitamin D (target ≥30 ng/mL before starting therapy), a comprehensive metabolic panel, and a DXA scan performed within the prior 24 months [4]. Some insurers also require bone turnover markers such as CTX (C-terminal telopeptide) or P1NP (procollagen type 1 N-terminal propeptide), though this varies by plan.

Hypocalcemia must be corrected before the first injection. The Endocrine Society recommends ensuring adequate calcium (1,000-1,200 mg daily) and vitamin D supplementation throughout the 12-month treatment course [5]. Washington Medicaid specifically requires documentation that vitamin D deficiency has been addressed prior to approval.

A lipid panel and cardiovascular risk assessment are also expected given the boxed warning. Some Washington commercial plans require documentation that the patient's 10-year ASCVD risk has been formally calculated using the ACC/AHA pooled cohort equations.

Prior Authorization for Evenity in Washington

Washington Medicaid covers romosozumab for severe osteoporosis, but prior authorization is mandatory. Commercial plans in the state (Premera, Regence, Molina, Coordinated Care) follow similar protocols with minor variations.

The typical PA package requires: a DXA scan showing a T-score of −2.5 or worse, documentation of fracture history or FRAX score, evidence that the patient has tried or cannot tolerate bisphosphonates (alendronate, risedronate, or zoledronic acid), lab results confirming corrected hypocalcemia and adequate vitamin D, and a cardiovascular risk attestation [6].

Turnaround time for Washington Medicaid PA decisions is generally 5-7 business days for standard requests. Urgent requests (for example, a patient with a recent vertebral compression fracture) may be processed within 72 hours. Commercial plans vary but most respond within 10-14 business days.

If the initial PA is denied, Washington patients have the right to appeal. The denial letter must include the specific clinical criteria that were not met. In many cases, a peer-to-peer review between your prescriber and the plan's medical director resolves the issue. Washington's Office of the Insurance Commissioner can assist if the appeal is unsuccessful.

Amgen offers the Evenity Complete program, which provides copay assistance for commercially insured patients (reducing out-of-pocket costs to as low as $5 per month) and free drug for uninsured patients who meet income criteria [7].

Specialty Pharmacy Access in Washington

Romosozumab is a specialty medication distributed through a limited pharmacy network. In Washington, patients can access it through specialty pharmacies affiliated with major health systems (UW Medicine, Virginia Mason, MultiCare) or through national specialty pharmacies that ship to WA addresses (Accredo, CVS Specialty, Optum Specialty).

Washington also has licensed 503A compounding pharmacies, though it is important to understand that romosozumab itself is a biologic monoclonal antibody and is not compounded. The 503A availability referenced in state access data pertains to supportive medications (such as calcium/vitamin D preparations or other osteoporosis agents) rather than to romosozumab itself. Evenity is only available as a manufactured product from Amgen in prefilled syringes.

Once prior authorization is secured, the specialty pharmacy ships the prefilled syringes to your home in temperature-controlled packaging. Delivery within Washington typically takes 3-5 business days after PA approval. The pharmacy will coordinate with you on delivery timing since the medication requires refrigeration (36°F-46°F) and should not sit on a doorstep.

Each monthly shipment contains two 105 mg/1.17 mL prefilled syringes. The syringes should be removed from the refrigerator and allowed to reach room temperature for 30 minutes before injection.

Cost and Insurance Coverage in Washington

The wholesale acquisition cost for romosozumab is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-dose course. Your actual out-of-pocket cost depends on your insurance structure.

Washington Medicaid (Apple Health) covers Evenity with prior authorization for patients meeting severe osteoporosis criteria. Copays under Medicaid are minimal (typically $0-$3 per fill). Washington's Medicaid preferred drug list classifies romosozumab as a non-preferred specialty drug requiring PA, but approval rates are high when documentation is complete [6].

For Medicare Part B beneficiaries in Washington, romosozumab is covered as a physician-administered drug when given in a clinic setting, or under Part D if self-administered at home. The Part B coinsurance is 20% after the deductible, which can mean $365 or more per injection without supplemental coverage. Medicare Advantage plans in Washington (Humana, UnitedHealthcare, Kaiser) each maintain their own PA protocols.

Commercial insurance coverage varies. Most plans cover Evenity after bisphosphonate failure, with specialty tier copays ranging from $50-$500 per month before manufacturer copay cards are applied.

Treatment Timeline: From Consultation to First Injection

The timeline from your first appointment to receiving your first romosozumab injection in Washington typically spans 3-6 weeks. Here is a realistic breakdown.

Week 1: Initial telehealth or in-person consultation. Prescriber reviews your history, orders labs if not already available, and discusses cardiovascular risk. Week 2: Lab results return. If vitamin D is low, supplementation begins immediately (50,000 IU weekly for 8 weeks is a common repletion protocol). Week 2-3: Prescriber submits prior authorization with complete documentation. Week 3-4: PA decision received. If approved, prescription is sent to specialty pharmacy. Week 4-5: Specialty pharmacy contacts you, verifies insurance, arranges delivery. Week 5-6: First injection administered, either self-injected at home after training or given in-clinic.

If your labs are already current and your vitamin D is replete, this timeline can compress to as little as 2-3 weeks. Delays most commonly occur at the prior authorization stage, particularly if initial documentation is incomplete.

Which Providers Can Prescribe Evenity in Washington

Washington state law permits physicians (MDs and DOs), nurse practitioners (ARNPs), and physician assistants (PAs) to prescribe romosozumab. There is no specialty restriction. A family medicine physician can prescribe it, though most PA reviewers look for documentation from or in consultation with an endocrinologist, rheumatologist, or orthopedic specialist.

In practice, the providers most commonly prescribing romosozumab in Washington include endocrinologists at academic centers (University of Washington, Washington State University), rheumatologists in private practice, and orthopedic surgeons managing patients after osteoporotic fractures. Telehealth platforms specializing in bone health have expanded access for patients in rural Washington counties where these specialists are scarce.

ARNPs in Washington have full practice authority and can independently prescribe, order labs, and submit prior authorizations without physician oversight. This is particularly relevant for patients in eastern Washington or rural communities served primarily by nurse practitioners.

Transferring a Romosozumab Prescription to Washington

If you are relocating to Washington mid-treatment, your existing romosozumab prescription can transfer. Washington accepts out-of-state prescriptions for non-controlled substances. Your new pharmacy (or the same national specialty pharmacy if it operates in WA) will contact your previous prescriber to verify the prescription.

The more practical challenge is insurance continuity. If your new Washington-based plan differs from your prior plan, a new prior authorization will likely be required. Request your complete treatment records (including the original PA approval letter, DXA results, lab work, and documentation of doses received) before your move. This documentation accelerates the new PA process.

If you have received 6 of 12 monthly doses in another state, the remaining 6 doses can be authorized in Washington. Your prescriber should document the number of doses already administered, as romosozumab is strictly limited to 12 lifetime doses due to the waning of its bone-forming effect and the cardiovascular safety signal beyond one year [1].

After the 12-Month Course: What Comes Next

Romosozumab's bone-forming effect is time-limited. The FRAME trial extension data showed that bone mineral density gains are lost within 12 months of stopping romosozumab unless an antiresorptive agent is started immediately [8]. Washington prescribers should have a sequential therapy plan in place before the 12th injection.

The standard transition protocol is romosozumab for 12 months followed by denosumab (Prolia) every 6 months or zoledronic acid (Reclast) annually. The ARCH trial used this romosozumab-to-alendronate sequence and demonstrated sustained fracture risk reduction at 24 months [2]. Your Washington provider will submit a separate prior authorization for the follow-on agent, which is typically approved without difficulty given the established treatment sequence.

DXA scanning is recommended 12 months after completing the romosozumab course to document the bone density response. Most Washington plans cover annual DXA scans for patients on active osteoporosis therapy.